Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
NBRV was delisted on the 31st of July, 2023.
53 hedge funds and large institutions have $21.7M invested in Nabriva Therapeutics plc Ordinary Shares Ireland in 2020 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 10 closing their positions.
103,600% more call options, than puts
Call options by funds: $1.04M | Put options by funds: $1K
100% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 6
51% more capital invested
Capital invested by funds: $14.3M → $21.7M (+$7.36M)
30% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 10
6% more funds holding
Funds holding: 50 → 53 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.46M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$3.64M |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$750K |
| 4 |
State Street
Boston,
Massachusetts
|
+$538K |
| 5 |
WG
Winton Group
London,
United Kingdom
|
+$245K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$980K |
| 2 |
FNC
First National Corp
Rockland,
Massachusetts
|
-$941K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$211K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$145K |
| 5 |
Renaissance Technologies
New York
|
-$131K |
NBRV Hedge Fund Activity: Q2 2020 in Review
53 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) for Q2 2020, worth a combined $21.7M — up 51% from $14.3M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new NBRV positions and 10 closed out — a net gain of 3 holders — while 12 added to existing stakes and 6 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $5.46M. The largest seller was Vivo Capital, exiting entirely with an estimated $980K sold.
- 53 institutional investors held Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) as of Q2 2020, up from 50 in Q1 2020.
- Funds reported $21.7M of Nabriva Therapeutics plc Ordinary Shares Ireland stock for Q2 2020, up 51% quarter-over-quarter.
- 13 funds opened new Nabriva Therapeutics plc Ordinary Shares Ireland positions in Q2 2020 and 10 closed out, a net change of +3 holders.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland buyer in Q2 2020 was Fidelity Investments, an estimated $5.46M added.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland seller in Q2 2020 was Vivo Capital, an estimated $980K sold.
Based on aggregated 13F filings for Q2 2020.